



ProbioMed™ References

1. Petersen, et al. (2012). Consumption of probiotics increases the effect of regulatory T cells in transfer colitis. *Inflammatory Bowel Diseases*, 18(1), 131-142. doi:10.1002/ibd.21709.
2. Zeuthen, et al. (2010). *Lactobacillus acidophilus* induces a slow but more sustained chemokine and cytokine response in naïve foetal enterocytes compared to commensal *Escherichia coli*. *BMC Immunology*, 11, 2.
3. Chen, C.-C., Chiu, C.-H., Lin, T.-Y., Shi, H. N., & Walker, W. A. (2009). Effect of probiotics *Lactobacillus acidophilus* on *Citrobacter rodentium* colitis: The role of dendritic cells. *Pediatric Research*, 65(2), 169–175.
4. Foligné B, et al. (2007). A key role of dendritic cells in probiotic functionality. *PLoS ONE* 2:e313.
5. Tejada-Simon MV, et al. (1999). Ingestion of yogurt containing *Lactobacillus acidophilus* and *Bifidobacterium* to potentiate immunoglobulin A responses to cholera toxin in mice. *J Dairy Sci.* 82, 649-660.
6. Leyer GJ, et al. (2009). Probiotic effects on cold and influenza-like symptom incidence and duration in children. *Pediatrics*. 124, e172-e179.
7. Saber R, et al. (2011). Lipoteichoic acid-deficient *Lactobacillus acidophilus* regulates downstream signals. *Immunotherapy*. 3(3),337.
8. Björklund, et al. (2011). Gut microbiota of healthy elderly NSAID users is selectively modified with the administration of *Lactobacillus acidophilus* NCFM and lactitol. *Age*, 34(4), 987-999. doi:10.1007/s11357-011-9294-5.
9. Engelbrektsen, et al. (2009). Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. *J Med Microbiol.* 58, 663-670.
10. Engelbrektsen AL, et al. (2006). Analysis of treatment effects on the microbial ecology of the human intestine. *FEMS Microbiol Ecol.* 57, 239–250.
11. Sui J, et al. (2002). 16S ribosomal DNA analysis of the faecal lactobacilli composition of human subjects consuming a probiotic strain *Lactobacillus acidophilus* NCFM. *J Appl Microbiol.* 93, 907-912.
12. Cross ML, et al. (2002). Dietary intake of *Lactobacillus rhamnosus* HN001 enhances production of both TH1 and Th2 cytokines in antigen-primed mice. *Med Microbiol Immunol.* 191, 49-53.
13. Wagner RD, et al. (2000). Effects of probiotic bacteria on humoral immunity to *Candida albicans* in immunodeficient bg/bg-nu/nu and bg/bg-nu/+ mice. *Rev Iberoam Micol.* 17, 55-59.
14. Wagner RD, et al. (2000). Probiotic effects of feeding heat-killed *Lactobacillus acidophilus* and *Lactobacillus casei* to *Candida albicans*-colonized immunodeficient mice. *J Food Prot.* 63, 638-644.

15. Dunn SR, et al. (1998). Effect of oral administration of freeze-dried *Lactobacillus acidophilus* on small bowel bacterial overgrowth in patients with end stage kidney disease: reducing uremic toxins and improving nutrition. *Int Dairy J.* 8, 545-553.
16. Simenhoff ML & Dunn SR. (1996). Altered gut flora in uremia. *J Renal Nutr.* 6, 68-74.
17. Waitzberg DL, et al. (2012). Effect of synbiotic in constipated adult women – A randomized, double-blind, placebo-controlled study of clinical response, *Clinical Nutrition* (2012), [Accepted manuscript].
18. Ouwehand AC, et al. (2009). Influence of a combination of *Lactobacillus acidophilus* NCFM and lactitol on healthy elderly: intestinal and immune parameters. *Br J Nutr.* 101, 367-375.
19. Fisberg M, et al. (2002). Effect of oral nutritional supplementation with or without synbiotics and sickness and catch-up growth in preschool children. *Int Pediatr.* 17,216-222.
20. Polewski MA, Krueger CG, Reeda JD, Leyer G. (2016). Ability of cranberry proanthocyanidins in combination with a probiotic formulation to inhibit in vitro invasion of gut epithelial cells by extra-intestinal pathogenic *E. coli*. *Journal of Functional Foods*, 25, 123-134. doi:10.1016/j.jff.2016.05.015.
21. Lönnemark E, Friman V, Lappas G, Sandberg T, Berggren A, Adlerberth I. (2010). Intake of *Lactobacillus plantarum* reduces certain gastrointestinal symptoms during treatment with antibiotics. *Journal of Clinical Gastroenterology*, 44(2), 106-112. doi:10.1097/mcg.0b013e3181b2683f.
22. Nobaek, S. (2000). Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. *The American Journal of Gastroenterology*, 95(5), 1231-1238. doi:10.1016/s0002-9270(00)00807-8.
23. Foligne, B. (2007). Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. *World Journal of Gastroenterology*, 13(2), 236. doi:10.3748/wjg.v13.i2.236.
24. Paineau D, et al. (2008). Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. *FEMS Immunol Med Microbiol.* 53, 107-13.
25. Bosch M, Méndez M, Pérez M, Farran A, Fuentes MC, Cuñé J. (2012). *Lactobacillus plantarum* CECT7315 and CECT7316 stimulate immunoglobulin production after influenza vaccination in elderly. *Nutr Hosp.* 27(2),504-9.
26. Ouwehand, et al. (2009). Specific probiotics alleviate allergic rhinitis during the birch pollen season. *World Journal of Gastroenterology : WJG*, 15(26), 3261–3268.
27. Rizzardini G, Eskesen D, Calder PC, Capetti A, Jespersen L, Clerici M. (2012). Evaluation of the immune benefits of two probiotic strains *Bifidobacterium animalis* ssp. *lactis*, BB-12® and *Lactobacillus paracasei* ssp. *paracasei*, L. casei 431® in an influenza vaccination model: a randomised, double-blind, placebo-controlled study. *Br J Nutr.* 107(6),876-84.
28. Guillemard E, Tondu F, Lacoïn F, Schrezenmeir J. (2010). Consumption of a fermented dairy product containing the probiotic *Lactobacillus casei* DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. *Br J Nutr.* 103(1),58-68.

29. Alipour, et al. (2014). Effects of *Lactobacillus casei* supplementation on Confidential 14 disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial. *Int J Rheum Dis.* 17(5),519-27.
30. Endo, et al. (2011). Efficacy of *Lactobacillus casei* treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. *J Gastroenterol.* 46(7),894-905.
31. D'Inca, et al. (2011). Rectal administration of *Lactobacillus casei* DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. *Dig Dis Sci.* 56(4),1178-87.
32. Braga TD, da Silva GA, de Lira PI, de Carvalho Lima M. (2011). Efficacy of *Bifidobacterium breve* and *Lactobacillus casei* oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: a double-blind, randomized, controlled trial. *Am J Clin Nutr.* 93(1),81-6.
33. Hulston CJ, Churnside AA, Venables MC. (2015). Probiotic supplementation prevents high-fat, overfeeding-induced insulin resistance in human subjects. *Br J Nutr.* 113(4),596-602.
34. Ishikawa, et al. (2011). Beneficial effects of probiotic *bifidobacterium* and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. *Digestion.* 84(2),128-33.
35. Del Piano, et al. (2010). The use of probiotics in healthy volunteers with evacuation disorders and hard stools: a double-blind, randomized, placebo-controlled study. *J Clin Gastroenterol.* 44 Suppl 1:S30-4.
36. Asemi Z, Zare Z, Shakeri H, Sabihi SS, Esmailzadeh A. (2013). Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. *Ann Nutr Metab.* 63(1-2),1-9.
37. Neville BA, O'Toole PW. (2010). Probiotic properties of *Lactobacillus salivarius* and closely related *Lactobacillus* species. *Future Microbiol,* 5, 759-774.
38. Iwamoto et al. (2010). Effects of probiotic *Lactobacillus salivarius* WB21 on halitosis and oral health: an open-label pilot trial. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology,* 110(2), 201-208. doi:10.1016/j.tripleo.2010.03.032.
39. Nishihara T, Suzuki N, Yoneda M, Hirofuji T. (2014). Effects of *Lactobacillus salivarius*-containing tablets on caries risk factors: a randomized open-label clinical trial. *BMC Oral Health.* 14,110.
40. Gill HS, et al. (2001). Dietary probiotic supplementation to enhance cellular immunity in the elderly. *Br J Biomed Sci.* 58,94-96.
41. Caceres P, et al. (2011). Effects of *Lactobacillus rhamnosus* HN001 on acute respiratory infections and intestinal secretory IgA in children. *J Ped Inf Dis.* 5, 353-362.
42. Prescott SL, et al. (2008). Supplementation with *Lactobacillus rhamnosus* or *Bifidobacterium lactis* probiotics in pregnancy increases cord blood interferon-c and breast milk transforming growth factor-b and immunoglobulin A detection. *Clin Exp Allergy.* 38,1606-14.
43. Lahtinen, et al. (2012). Probiotic cheese containing *Lactobacillus rhamnosus* HN001 and *Lactobacillus acidophilus* NCFM® modifies subpopulations of fecal lactobacilli and *Clostridium difficile* in the elderly. *Age,* 34(1), 133–143.

44. Shu Q and Gill HS. (2002). Immune protection mediated by the probiotic *Lactobacillus rhamnosus* HN001(DR20TM) against *Escherichia coli* O157:H7 infection in mice. *FEMS Immunol Med Microbiol.* 34, 59-64.
45. Gill HS, et al. (2001). Protection against translocating *Salmonella typhimurium* infection in mice by feeding the immuno-enhancing probiotic *Lactobacillus rhamnosus* strain HN001. *Medical Microbiology and Immunology.* 190, 97-104.
46. Nagala R & Routray C. (2010). Multispecies probiotic supplement minimizes symptoms of irritable bowel syndrome, A clinical case study. 2010.
47. Miki K, et al. (2007). Effect of *Bifidobacterium bifidum* fermented milk on *Helicobacter pylori* and serum pepsinogen levels in humans. *J Dairy Sci.* 90(6),2630-40.
48. Olivares M, Castillejo G, Varea V, Sanz Y. (2014). Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of *Bifidobacterium longum* CECT 7347 in children with newly diagnosed coeliac disease. *Br J Nutr.* 112(1),30-40.
49. Macfarlane S, Cleary S, Bahrami B, Reynolds N, Macfarlane GT. (2013). Synbiotic consumption changes the metabolism and composition of the gut microbiota in older people and modifies inflammatory processes: a randomised, double-blind, placebo-controlled crossover study. *Aliment Pharmacol Ther.* 38(7),804-16.
50. Malaguarnera M, et al. (2012). *Bifidobacterium longum* with fructo-oligosaccharides in patients with non-alcoholic steatohepatitis. *Dig Dis Sci.* 57(2),545-53.